South Korea · General

Celltrion's Truxima leads U.S. prescription market in Feb.

· By Choi Kyong-ae
Story summary

SEOUL, April 7 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Tuesday its biosimilar Truxima, used to treat blood cancers, claimed the largest share of prescriptions in the United States in February.

Read at South Korea

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.